Bio Green Med (BGMS) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Roth MKM | Maintained | Buy | $11.00 from $21.00 | May 3, 2024 |
| Roth MKM | Maintained | Buy | $21.00 from $16.00 | Dec 19, 2023 |
| Brookline Capital | Downgraded | Buy → Hold | — | Dec 19, 2023 |
| Oppenheimer | Maintained | Outperform | $8.00 | May 25, 2023 |
| Oppenheimer | Maintained | Outperform | $8.00 from $10.00 | Mar 7, 2023 |
Frequently asked questions
Is BGMS a buy, sell, or hold?
Analysts covering Bio Green Med currently average a Hold rating: 0 buy, 1 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on BGMS?
On May 3, 2024, Roth MKM maintained Bio Green Med at Buy with a price target of $11.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.